EAN 2025: Transforming the Diagnostic Pathway in the Era of Disease-Modifying Therapies for Alzheimer’s Disease

At the Nordic Evening during EAN 2025, Dr. Kristian Steen Frederiksen addressed critical questions shaping the future of Alzheimer’s diagnosis: Is the presence of amyloid alone sufficient to establish a diagnosis of Alzheimer’s disease? And what is the actual risk of amyloid positivity progressing to cognitive impairment in asymptomatic individuals?
In this MEDtalk, Dr. Frederiksen shares his expert perspective on these pivotal issues and explores how emerging disease-modifying therapies are redefining diagnostic and treatment strategies.